46 results on '"Tan, Wan Ling"'
Search Results
2. Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma
3. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer
4. A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
5. Multispectral raster-scanning optoacoustic mesoscopy differentiate lesional from non-lesional atopic dermatitis skin using structural and functional imaging markers
6. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
7. Detection of circulating tumor DNA with ultradeep sequencing of plasma cell‐free DNA for monitoring minimal residual disease and early detection of recurrence in early‐stage lung cancer
8. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis
9. Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non–Small-Cell Lung Cancer
10. Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure
11. Heterogeneity of PD-L1 expression among resected EGFR-mutated NSCLC and prognostic implications.
12. Identifying correlates of post treatment responses for unresectable locally advanced non-small cell lung cancer (LA NSCLC).
13. EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients
14. Dearth of smoking-induced mutations in NSRO-driven non-small-cell lung cancer despite smoking exposure
15. Novel therapeutic targets on the horizon for lung cancer
16. Supplementary Data from Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
17. Real world outcomes of patients with non-clear cell renal cell carcinoma: A single Asian centre experience.
18. Is There a Unicorn Among the Uncommon EGFR Mutations?
19. Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance
20. Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients
21. Abstract 5114: Ultra-sensitive detection of minimal residual disease (MRD) through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer (NSCLC)
22. PD-L1 score as a prognostic biomarker in Asian patients with early-stage, EGFR-mutated lung cancer.
23. PD-L1 Score as a Prognostic Biomarker in Asian Early-Stage EGFR-Mutated Lung Cancer
24. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer
25. Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC
26. Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
27. From presentation to paper: Gender disparities in oncological research
28. Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
29. Abstract CT203: A phase II trial of ipilimumab in combination with nivolumab in EBV-associated advanced nasopharyngeal carcinoma (NCT03097939)
30. From presentation to paper: Gender disparities in oncological research
31. Prevalence of ARV7 in Asian metastatic castrate-resistant prostate cancer (mCRPC) patients using multiple detection platforms.
32. From presentation to paper: Gender disparities in oncological research.
33. Clonal MET Amplification as a Determinant of Tyrosine Kinase Inhibitor Resistance in Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
34. A multigene expression score for predicting response to anti-PD-1/PD-L1 therapy for clear cell renal cell cancer patients.
35. Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
36. Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
37. Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer
38. Comparison of hepatocellular carcinoma in Eastern versus Western populations
39. Advances in systemic treatment for nasopharyngeal carcinoma
40. Elucidating the genomic and transcriptomic landscape of L858R vs ex19del EGFR-mutated NSCLC.
41. Component-based software development for report generation
42. EGFRMutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients
43. Influence of the KDM4Ars586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients
44. An Immunohistochemical Study on the Distribution and Frequency of T Regulatory Cells in Pancreatic Islets of NOD Mice During Various Stages of Spontaneous and Cyclophosphamide-Accelerated Diabetes
45. Oncogene-Driven Non-Small Cell Lung Cancers in Patients with a History of Smoking Lack Smoking-Induced Mutations.
46. The continuing role of epidermal growth factor receptor tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.